Analysts think CRMD stock price could increase by 178%
Apr 05, 2025, 11:25 AM
60.24%
What does CRMD do
CorMedix is a pharmaceutical company based in New Jersey, focused on developing therapeutic products, notably DefenCath, an antimicrobial solution for preventing catheter-related bloodstream infections in kidney failure patients. The company went public in 2010 and has also sponsored research on taurolidine for rare pediatric tumors.
8 analysts think CRMD stock price will increase by 178.50%. The current median analyst target is $16.32 compared to a current stock price of $5.86. The lowest analysts target is $12.12 and the highest analyst target is $19.95.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.